Wolfgang Miesbach: CMA CAR-T Induces Immune Reset and Durable Remission in Refractory ITP – EHA 2026 Late-Breaking Update
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Jinhui Shu et al, adding։
“Looking ahead to EHA 2026 next week, I am particularly interested in an upcoming late-breaking presentation:
- BCMA CAR-T Cell Therapy Induces Comprehensive Immune Resetting and Durable Remission in Refractory Primary Immune Thrombocytopenia
Targeting plasma cells and pathogenic antibody production represents a promising mechanistic shift beyond traditional B-cell–directed approaches.
It will be exciting to see how these strategies translate into clinical responses and immune modulation.”
Title: BCMA CAR-T cell therapy induces comprehensive immune resetting and durable remission in refractory primary immune thrombocytopenia
Authors: Jinhui Shu, Min Xu, Wei Xie, Lin Liu, Peiru Li, Hongjian Li, James Bussel, Yu Hu, Heng Mei
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 18, 2026, 23:52Chinua Onyebuchi: Applications Now Open for the European Stroke Master Programme
-
Jul 18, 2026, 22:43Exploring the Ultra-Late Window for Stroke Treatment – International Journal of Stroke
-
Jul 18, 2026, 21:38Swastik Sharma Deviprasad Bhat: A One-Minute Guide to Recognizing Stroke
-
Jul 18, 2026, 21:05Federica Fedele: From One-Size-Fits-All to Personalized Care
-
Jul 18, 2026, 21:04Sandra Rodríguez Coma: A Great Experience With the Werfen Team at ISTH 2026
-
Jul 18, 2026, 20:58Heghine Khachatryan: Cancer-Associated ATE – An Underrecognized Challenge in Modern Oncology
-
Jul 18, 2026, 20:57Barbara Adams Krolak: The Science Was Even Hotter Than Paris
-
Jul 18, 2026, 20:15Ahmed Kotb: Exploring Qualitative Platelet Defects
-
Jul 18, 2026, 20:08Bianca Heidersdorf: Shaping the Future of Bleeding Disorders Support at ISTH 2026